Arrowhead Pharmaceuticals, Inc. (LSX:A2AGYB) Financings

Arrowhead Pharmaceuticals, Inc.

Financings

RaiseDate
0.00% convertible senior notes due 2032
Closed: US$625M raised · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets
Use of proceeds: About $42.8 million for capped call transactions; remainder for general corporate purposes incl. R&D, clinical trials and commercial launch preparation
Feb 5, 2026
Public offering of common stock and pre-funded warrants
Closed: US$200M raised · US$64.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets
Use of proceeds: General corporate purposes incl. working capital, R&D, clinical trials and commercial launch preparation; may prepay Sixth Street loans
Feb 5, 2026
Strategic investment of common stock
Closed: US$325M raised · US$27.25 a share
Buyers: Sarepta ($325 million of Arrowhead common stock at $27.25 per share)
Oct 21, 2025
Strategic investment of common stock
Closed: US$325M raised · US$27.25 a share
Buyers: Sarepta Therapeutics ($325 million equity investment priced at $27.2507); Sarepta ($325 million of Arrowhead common stock at $27.25 per share)
Feb 10, 2025

Read by 6ix AI from the company's releases